Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression
This study has been completed.
Germans Trias i Pujol Hospital
First Posted: December 18, 2009
Last Update Posted: October 25, 2012
Information provided by (Responsible Party):
Dra. EUGENIA NEGREDO PUIGMAL, Fundacio Lluita Contra la SIDA
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||December 2011|
|Primary Completion Date:||December 2011 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Echeverría P, Bonjoch A, Puig J, Moltó J, Paredes R, Sirera G, Ornelas A, Pérez-Álvarez N, Clotet B, Negredo E. Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study. PLoS One. 2014 Feb 4;9(2):e84676. doi: 10.1371/journal.pone.0084676. eCollection 2014.